AstraZeneca spins out antibiotics R&D
This article was originally published in Scrip
AstraZeneca is to spin out its early-stage small molecule antibiotics pipeline into a standalone subsidiary, into which it will invest $40m. The new company is expected to be led by and include staff from AstraZeneca's Innovative Medicines Unit. Some 95 staff in Waltham, Massachusetts will be affected; they are likely to take up positions at the new company or move to other parts of AZ.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.